Jazz, Hikma Must Face Bulk Of Xyrem Antitrust Suit

By Bryan Koenig · August 28, 2024, 7:33 PM EDT

Jazz Pharmaceuticals and Hikma Pharmaceuticals appear bound for trial against most solo insurer and class action antitrust claims over alleged efforts to block generic competitors to Jazz's Xyrem narcolepsy drug, under...

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Order

Case Information

Case Title

In re Xyrem (Sodium Oxybate) Antitrust Litigation

Case Number

3:20-md-02966

Court

California Northern

Nature of Suit

Anti-Trust

Date Filed

December 16, 2020

Featured Stories

3 Companies That Could Restructure In The 2nd Half Of 2024 No Photo Available

Hilary Russ

With elevated borrowing rates and other macroeconomic headwinds lingering, struggling companies could end up resorting to drastic meas... (more story)

Girardi Denies Fraud Charges, Alex Jones Biz Sale Proposed No Photo Available

Yun Park

Disbarred attorney Tom Girardi has denied stealing from any of his clients, asking a judge to toss wire fraud charges. Meanwhile, a co... (more story)

Chapter 11 Check-In: Yellow Corp.'s $1.5B Bankruptcy No Photo Available

Clara Geoghegan

It's been more than a year since national trucking giant Yellow Corp. landed in Delaware's bankruptcy court following contentious unio... (more story)